Anne-Sofie Bjerrum

Anne-Sofie Bjerrum

Auto-generated profile, based on publicly available information

Anne-Sofie Bjerrum

Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2024 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
LLLuis Pérez Pérez de Llano
Luis Pérez Pérez de Llano
GSGhislaine Scelo
Ghislaine Scelo
TTTrung N. Tran
Trung N. Tran
TLTham T. Le
Tham T. Le
MFMalin Fagerås
Malin Fagerås
DPDavid B. Price
David B. Price
Rationale: There is no consensus on criteria to include in an asthma remission definition in real life. Factors associated with achieving remission after biologic initiation remain poorly understood. Objectives: To quantify the proportion of adults with severe asthma achieving multidomain-defined remission after biologic initiation and identify prebiologic characteristics associated with achieving remission that may be used to predict it. Methods: This was a longitudinal cohort study using data from 23 countries from the International Severe Asthma Registry. Four asthma outcome domains were assessed in the 1 year before and after biologic initiation. A priori–defined remission cutoffs were: 0 exacerbations/yr, no long-term oral corticosteroid (LTOCS), partly/well-controlled asthma, and percent predicted FEV1 ⩾ 80%. Remission was defined using two (exacerbations + LTOCS), three (+control or +lung function), and four of these domains. The association between prebiologic characteristics and postbiologic remission was assessed by multivariable analysis. Measurements and Main Results: A total of 50.2%, 33.5%, 25.8%, and 20.3% of patients met criteria for two-, three- (+control), three- (+lung function), and four-domain remission, respectively. The odds of achieving four-domain remission decreased by 15% for every additional 10 years of asthma duration (odds ratio, 0.85; 95% confidence interval, 0.73–1.00). The odds of remission increased in those with fewer exacerbations per year, lower LTOCS daily dose, better control, and better lung function before biologic initiation. Conclusions: One in five patients achieved four-domain remission within 1 year of biologic initiation. Patients with less severe impairment and shorter asthma duration at initiation had a greater chance of achieving remission after biologic treatment, indicating that biologic treatment should not be delayed if remission is the goal.

4 October 2022 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
MSMarianne Baastrup Soendergaard
Marianne Baastrup Soendergaard
SHSusanne Hansen
Susanne Hansen
ABAnne-Sofie Bjerrum
Anne-Sofie Bjerrum
OHOle Hilberg
Ole Hilberg
SLSofie Lock-Johansson
Sofie Lock-Johansson
CPCeleste Porsbjerg
Celeste Porsbjerg
Background: Phase III regulatory trials show that anti-interleukin (IL)-5 biologics efficiently reduce exacerbations and the use of maintenance oral corticosteroids (mOCS) in patients with severe eosinophilic asthma. However, patients eligible for these trials differ significantly compared with real-life severe asthma populations. Therefore, our aim was to explore efficacy in a real-life setting. The Danish Severe Asthma Register (DSAR) is a complete, nationwide register that comprises all Danish patients on biological therapy for severe asthma.Methods: This prospective study identified patients in the DSAR who were complete responders to anti-IL-5 biologics after 1 year of treatment. A complete response was defined as resolution of the parameter setting the indication,i.e.recurrent exacerbations and/or use of mOCS.Results: A total of 289 out of 502 (58%) patients were complete responders to anti-IL-5 biologics after 12 months. Complete responders had greater improvements in forced expiratory volume in 1 s and Asthma Control Questionnaire (ACQ) score compared with noncomplete responders (Δ 210versus30 mL; p<0.0001 and Δ −1.04versus−0.68; p=0.016, respectively). A complete response was predicted by age at onset, less severe disease at baseline (i.e.no mOCS and lower ACQ score) and higher blood eosinophils.Conclusions: More than half of Danish patients treated with anti-IL-5 biologics for severe asthma achieve a complete response to treatment, thereby becoming free from asthma exacerbations and the need for mOCS. Complete responders also achieved superior effects on lung function and symptoms compared with noncomplete responders.

5 March 2025 in Journal of Asthma
Verified
Journal Article
Open access
KHKjell Erik Julius Håkansson
Kjell Erik Julius Håkansson
RIRikke Ibsen
Rikke Ibsen
NKNiels Steen Krogh
Niels Steen Krogh
MSMarianne Baastrup Soendergaard
Marianne Baastrup Soendergaard
SHSusanne Hansen
Susanne Hansen
CPCeleste Porsbjerg
Celeste Porsbjerg
IntroductionSevere asthma impacts work capacity, but little is known about the effects of biologic therapy on patients' ability to work. We aimed to assess the impact of biologic therapy for severe asthma on work capacity and workforce attachment.MethodsThis cohort study used the Danish Severe Asthma Register, comprising all Danish patients with severe asthma initiating biologic therapy. Earned income, hours worked, and workforce attachment tracked in national databases from one year prior to biologic therapy as well as during two years of biologic therapy. Outcomes were compared to age-, sex-, cohabitation- and residence-matched controls from the general population.ResultsOverall, 381 patients aged 20-62 years (52% females) were included. Annual weeks worked were lower among patients with severe asthma (adjusted incidence rate ratio (aIRR) 0.82 (0.80-0.84)), driven by increases in sick-leave (aIRR 2.77 (2.58-2.98)), unemployment (aIRR 1.38 (1.30-1.46)) and disability pension (aIRR 1.85 (1.76-1.94)).After initiating biologic therapy, patients saw modest increases in annual hours worked during the second year of treatment (aIRR 1.03 (1.03-1.04)). However, patients remained at risk for temporary (OR 1.83 (1.15-2.93)) and permanent (OR 2.67 (1.16-6.16)) workforce withdrawal.Patients achieving on-treatment remission worked significantly more hours compared to non- and clinical responders and had lower unemployment-, sick-leave and disability pension rates both at baseline and after two years.ConclusionBiologic therapy resulted in a modest increase in hours worked, yet patients remain at significant risk of early workforce withdrawal. Patients achieving remission had a stronger attachment to the workforce, also prior to biologic therapy.